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Abstract
Background: We experience many cases of liver metastasis from colorectal cancer, but synchronous occurrence of
intrahepatic cholangiocarcinoma (ICC) and liver metastasis from a rectal cancer is extremely rare. We herein report a
case of ICC coinciding with a liver metastasis from a known rectal carcinoma.
Case presentation: A 68-year-old man was referred to our hospital for investigation of multiple liver tumors. Total
colonoscopy and computed tomography (CT) revealed a rectal carcinoma, coinciding with liver metastasis. He was
planned to receive chemotherapy following rectal resection. During chemotherapy for the rectal cancer, one of the
liver tumors gradually grew after first shrinking. The following hepatectomy revealed the presence of intrahepatic
cholangiocarcinoma (ICC). Despite intensive chemotherapy for the ICC, he passed away 6 months after the hepatectomy.
Conclusions: We should also suspect the possibility of multiple primary cancers, even if the patient has a history
of cancer that is likely to cause metastatic lesions. When simultaneous neoplasms are diagnosed, systematic
treatment should be targeted to the tumor with the worst prognosis.
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Background
The occurrence of multiple primary malignancies in a
single organ is rare. There are several reports about syn-
chronous double primary malignancies of the liver. The
liver is the most frequent metastatic site of colorectal
cancer, and therefore, hepatic masses of patients who
have colorectal cancer are usually diagnosed as a metas-
tasis of colorectal cancer. There was a case report of
combined hepatocellular carcinoma-cholangiocarcinoma
harboring a metastasis of colon adenocarcinoma that
was treated with curable resection [1]. However, in our
case, one of several liver tumors gradually developed
during chemotherapy for the known rectal cancer. Hepa-
tectomy and pathology revealed it was an intrahepatic
cholangiocarcinoma (ICC), not a metastasis from a
rectal cancer. To our knowledge, this is the first case re-
port of such a simultaneous condition.
Case presentation
A 68-year-old man was referred to our hospital for in-
vestigation of multiple liver tumors. He had a history of
drinking shochu (60 g of alcohol per day). His medical
history was unremarkable with the exception of hyper-
tension. Serum biochemistry was as follows: aspartate
aminotransferase, 19 U/L; alanine aminotransferase,
19 U/L; total bilirubin, 0.1 mg/dL; carcinoembryonic
antigen (CEA), 6.0 ng/mL; cancer antigen 19-9 (CA 19-9),
2601 U/mL; alkaline phosphatase, 183 U/L; gamma-
glutamyl transpeptidase, 36 U/L. He was negative for
hepatitis B antigen and hepatitis C antibodies.
Computed tomography (CT) showed an enhanced
mass in the rectum and hypo-vascularized tumors in the
liver segment 2 (S2), segment 3 (S3), segment 5 (S5),
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segment 6 (S6), and segment 8 (S8) (Fig. 1). The largest
liver tumor had a diameter of 16 mm in S2. On positron
emission tomography-computed tomography (PET-CT),
abnormal fluorodeoxyglucose (FDG) uptake was seen at
the rectum (SUV-max 12.7) and the S2, S5, and S8 tu-
mors (SUV-max 10.2). Total colonoscopy revealed a rec-
tal carcinoma with a diameter of 3 cm that was located
10 cm distant from the anal verge.
He was diagnosed with rectal carcinoma coinciding with
liver metastasis. His preoperative staging was T4N1M1
stage IV (TNM classification). Numerous metastatic tu-
mors already occupied in the liver. We estimated that
61 % of the whole liver needed to be resected for the
complete excision. Therefore, he was planned to receive
chemotherapy following rectal resection to avoid liver
failure. Laparoscopic lower anterior resection was per-
formed, and pathological examination showed moder-
ately differentiated adenocarcinoma. According to the
TNM classification, pathological staging was diagnosed
as T3N2M1 (stage IV). The postoperative course was
uneventful, and he was discharged on the eighth post-
operative day.
The 10 courses of chemotherapy with capecitabine
and oxaliplatin (XELOX) plus bevacizumab (Bmab)
started a month after the operation and continued for
8 months. His tumor markers and liver mass decreased,
but after a short time, his tumor markers elevated again
(CEA 9.5 ng/mL, CA19-9 9027 U/mL). Therefore, we
changed the regimen to xeloda, irinotecan, and bevaci-
zumab (XELIRI + Bmab) and administered four courses.
Although almost all of the multiple liver tumors had
shrunk, the S2 tumor had grown as seen on a CT scan
(16 to 46 mm) and had FDG increased uptake (SUV-
max 11.9) on PET-CT. There were no signs of local, dis-
tant, or lymph node metastases.
We assumed the neoadjuvant chemotherapy was not
effective for the S2 lesion, so we decided to perform an
extended left hepatectomy. The images of the tumor are
shown in Fig. 1, and the clinical course is summarized in
Table 1. To our surprise, pathological examination
showed intrahepatic cholangiocarcinoma (ICC), moder-
ately differentiated, 55 mm × 50 mm × 40 mm, s1, ne1,
vp1, vv1, va0, b1. The carcinoma cells were positive for
CD10 and CD19 and negative for hepatocyte, glypican 3,
CK7, and CDX2 (Fig. 2). In the segments of hepatic tis-
sue, no metastatic adenocarcinoma was found. Accord-
ing to the TNM classification, the pathological stage of
the ICC was IVa (T4N0M0). The postoperative course
was uneventful, and he was discharged on the 12th post-
operative day.
A month later, PET-CT showed metastasis to the peri-
toneum, lumbar vertebra, lung, and skin. Biopsy of the
skin revealed a metastasis of cholangiocarcinoma.
Despite intensive chemotherapy with gemcitabine and
TS-1 (GS), and then gemcitabine and cisplatin (GC), he
passed away 6 months after the hepatectomy. An aut-
opsy was not performed at the request of the family.
Discussion
The main finding of the present case is that ICC unex-
pectedly existed in the liver among metastatic tumors
from colon cancer. Liver resection was scheduled after
the planned chemotherapy ended. However, contrary to
our expectation, ICC incidentally developed during the
chemotherapy for rectal cancer. Our case is instructive
of the need to pay attention to the possibility of multiple
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Fig. 1 Computed tomography (CT) showed an enhanced mass in
the rectum and hypo-vascularized tumors in the liver segment 2
(S2), segment 3 (S3), segment 5 (S5), segment 6 (S6), and segment 8
(S8). The largest liver tumor had a diameter of 16 mm in S2. Almost
all of the multiple liver tumors had shrunk after the neoadjuvant chemo-
therapy, but the S2 tumor had grown on the CT scan (16 to 46 mm)
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ICC is a relatively rare type of primary liver cancer,
which accounts for only 5–10 % of liver malignancies
[2]. Due to the increased life expectancy and improved
screening programs, the early detection ratio for mul-
tiple primary malignancies is expected to increase [3].
Synchronous cancers are defined as those where second-
ary tumors occur simultaneously or within 6 months of
diagnosis of the primary malignancy [4]. ICC sometimes
coexists with other cancers such as HCC [5–8], GIST
[9, 10], thyroid cancer [11], lymphoma [12], and renal
cell carcinoma [13]. Only one case with synchronous
double cancer consisting of combined HCC-ICC and
metastasis of a colon adenocarcinoma, which were
treated by curable resection, has been reported [1].
In our case, it was difficult to diagnose the ICC before
hepatectomy because the CT scan showed that there
were several tumors in the liver that were similar in
shape. Nam et al. reported a case of advanced synchron-
ous GIST and ICC, which was operable at initial presen-
tation, but progressed to become surgically unresectable
[9]. They concluded that the possibility of multiple primary
tumors must be considered as an alternative diagnosis.
In our case, the chemotherapy for colorectal cancer
was continued for 8 months because only the S2 site
Table 1 Clinical course, tumor size, and serum tumor markers
Months Clinical course Tumor size (CT) (mm) Tumor marker Evaluate the response
to treatmentS2 S3 S5 S6 S8 CEA (ng/mL) CA19-9 (U/mL)
0 At diagnosis 16 12 12 7 8 6 2601
1 Lower anterior rectal resection
2 XELOX + Bmab (1st course) 45.9 22,751
5 XELOX + Bmab (4th course) 18 0 0 0 0 5.4 515 PR
7 XELOX + Bmab (7th course) 4.4 166
9 XELOX + Bmab (9th course) 4.4 873
11 XELIRI + Bmab (1st course) 21 0 0 0 0 9.5 9027 SD
13 XELIRI + Bmab (4th course) 43.4 42,380 PD
14 Extended left hepatectomy 46 0 0 0 0
16 Gemcitabine + TS-1 10.9 2345




Fig. 2 a Microscopic findings of the S2 tumor show moderately differentiated intrahepatic cholangiocarcinoma (H&E staining ×400). b Carcinoma
cells are negative for CDX-2 (on immunohistochemistry, ×100). c Carcinoma cells are positive for CD19 (on immunohistochemistry, ×100).
d Carcinoma cells are positive for hepatocytes (on immunohistochemistry, ×100)
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tumor remained. ICC has been shown to be resistant to
common chemotherapy, with an unacceptably low re-
sponse rate [14]. Double gemcitabine and cisplatin ther-
apy is currently considered the first-line therapy for
patients with advanced disease [15, 16].
As we have shown in Table 1, CA 19-9 level had been
increased during the XELOX + Bmab therapy, we should
have taken into account the operation instead of chan-
ging the regimen to XELIRI + Bmab. If the S2 tumor
was resected earlier, this patient might have better prog-
nosis. Pintea et al. concluded that when simultaneous
neoplasms are diagnosed, systematic treatment can be
performed and this should target the tumor with the
worst prognosis [1]. We believe this is a suggestive case
in which we needed to take into account the possibility
of multiple primary tumors.
Conclusions
We experienced an instructive case from which we
learned to suspect the possibility of a cholangiocarcinoma
when we detect a solid lesion in the liver of a patient who
has colorectal cancer. We should also suspect the possibil-
ity of multiple primary cancers, even if the patient has a
history of cancer that is likely to cause metastatic lesions.
We need to try for an accurate diagnosis, and when simul-
taneous neoplasms are diagnosed, systematic treatment
should be targeted to the tumor with the worst prognosis.
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